Cart 0
Cart 0


Zero Negative was born from Jenn Greenhut’s diagnosis of Stage IV Triple-Negative breast cancer.

Doctors diagnose breast cancer by identifying which receptor is present. They run a series of tests for three main receptors, which will result in either a positive or negative. When all three main receptors (estrogen, progesterone, human epidermal growth factor) result as negative, it’s considered Triple-Negative.

With Triple-Negative breast cancer, chemotherapy is the most effective option for treatment. Triple-Negative breast cancer is the most aggressive form of the disease, and more difficult to treat due to all three main receptors NOT being present.

Despite the odds being unfavorable, Dennis Slamon and UCLA’s Jonsson Comprehensive Cancer Center, saved Jenn’s life.

“When I heard all of the characteristics of Triple-Negative, I was scared. Very scared. And to make matters even scarier - my doctor at UCLA (who I was meeting for the first time), Dr. Slamon, said that one of the positives about Triple-Negative was if it doesn’t come back in 5 years, then it has a very low chance of ever coming back…

But, if it does come back within that time, then it will be more aggressive and very hard to treat. Basically, he was saying I would most likely die from it, IF it comes back.

…It was really strange, and I remember this so well… as I was hearing the stats… I was weirdly starting to feel optimistic for the first time. I felt like I was stepping into my diagnosis, owning it in a way; AND I was realizing how safe I felt with Dr. Slamon.

I was finally accepting my prognosis, and then felt like, ‘Okay. If Dr. Slamon thinks he can do this, then I KNOW I can do this, and I WILL do this. I WILL be part of the 50% group that makes it past 5 years, and I’ll live a cancer free life once I get through all of this.

I’ll have perky boobs for the rest of my life, that’s cool no? I’ll surrender to the whole experience, like a student, and see what happens… AND, in the meantime, I’m going to figure out how to raise money for his research team at UCLA. Because God forbid, if this DOES come back (or doesn’t go away) - I better be part of the team looking for a cure!’

And, so it was, in Dr. Slamon’s office, when I decided to turn Stage IV Triple-Negative breast cancer into the best thing that would happen to me. 

I saw this as a sign from the universe, and a reason to fight for myself and others facing the same battle. With help from my friend, Orit Mesica, we designed the LOVE tote. A couple years later and cancer free, I am now just a girl fighting cancer in style, one bag at a time.

My goal is to utilize fashion to exude love and positivity, while supporting the doctors and scientists working to find a cure. Zero Negative donates a portion of all proceeds to UCLA’s Jonsson Cancer Center Foundation.”

Jenn's Headshot.jpg
Jenn's Signature.png

Since launching Zero Negative in 2017, Jenn has raised thousands of dollars for UCLA’s Jonsson Cancer Center Foundation. Through LOVE, positivity, and fashion, Jenn continues to inspire and teach women how to beat cancer by sharing her success story.

Pink Background.png
UCLA’s Medical Center

UCLA’s Medical Center

About UCLA’s Jonsson Cancer Center Foundation:

The UCLA Jonsson Cancer Center Foundation (JCCF) is a 501(c)(3) within UCLA that exists for the express purpose of raising and distributing funds to support life-changing cancer research at the UCLA Jonsson Comprehensive Cancer Center (JCCC).

The UCLA Jonsson Comprehensive Cancer Center has been designated “comprehensive” by the National Cancer Institute since 1976. Of the 69 NCI cancer center programs nationwide, only 47 receive the gold-star comprehensive status. UCLA's Jonsson Comprehensive Cancer Center (JCCC) continues to receive this honor for maintaining the highest standards of excellence in patient care, education, basic science, clinical research and cancer prevention.

Dennis Slamon serves as director of Clinical/Translational Research, and as director of the Revlon/UCLA Women's Cancer Research Program at JCCC. He is a professor of medicine, chief of the Division of Hematology/Oncology, and the executive vice chairman of research for UCLA's Department of Medicine.